Claims for Patent: 4,123,510

Summary for Patent: 4,123,510

Title:	Method for the determination of gonadotropins
Abstract:	A simple, sensitive, reliable and safe method for determining the concentration of pituitary gonadotropins is disclosed. The method involves concentration by ultrafiltration of a sample of body fluid, e.g. urine or serum from a subject, followed by determining the presence of the gonadotropin in the concentrated sample.
Inventor(s):	Banik; Upendra K. (Pierrefonds, CA), Givner; Morris L. (Pierrefonds, CA)
Assignee:	American Home Products Corp. (Del.) (New York, NY)
Application Number:	05/806,569
Patent Claims:	1. A method suitable for detection of luteinizing hormone in urine at a concentration as low as about 25 m.I.U./ml of urine and capable of detecting ovulation in a cycling woman, which comprises: (a) clarifying a sample of the urine to be tested; (b) contacting the urine sample before, during or after clarification with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemomycin so that adsorption of luteinizing hormone from the sample onto the membrane is substantially reduced; (c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby luteinizing hormone is retained in the sample; (d) continuing the ultrafiltration until the retentate sample is concentrated to one-tenth to one-five hundredth its original volume; (e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of luteinizing hormone in the retentate sample. 2. The method of claim 1 in which the luteinizing hormone is detected by a luteinizing hormone antiserum or a human chorionic gonadotropin antiserum which cross reacts with luteinizing hormone. 3. A method for detecting follicle stimulating hormone or human menopausal gonadotropin in urine at a concentration of 15 or more m.I.U./ml of urine, which comprises: (a) clarifying a sample of the urine to be tested; (b) contacting the urine sample before, during or after clarification with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemomycin so that adsorption of follicle-stimulating hormone or human menopausal gonadotropin from the sample onto the membrane is substantially reduced; (c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby follicle-stimulating hormone or human menopausal gonadotropin is retained in the sample; (d) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of follicle-stimulating hormone or human menopausal gonadotropin. 4. A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine which comprises: (a) clarifying a sample of the urine to be tested; (b) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane, said membrane having been prewashed with 0.1 to 5% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglogin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced, and said membrane having a molecular weight cut-off from about 5,000 to about 50,000 whereby the gonadotropin is retained in the sample; (c) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (d) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (e) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample. 5. The method of claim 4 wherein said ultrafiltration membrane is of the anisotropic type and in which the membrane has a molecular cut-off from about 10,000 to about 35,000. 6. The method of claim 4, wherein said ultrafiltration membrane is of the anisotropic type and the concentration of said solution of protein is from 0.1 to 1.0%. 7. The method of claim 4 wherein said clarifying step comprises filtration through a filter and which further comprises prewashing said filter with the aqueous solution of a protein. 8. A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine which comprises: (a) clarifying a sample of the urine to be tested; (b) contacting the urine sample before or after clarification with a sufficient amount of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin to give a concentration of the protein in the urine of from 0.001 to 1.0% so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced; (c) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000 whereby the gonadotropin is retained in the sample; (d) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (e) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (f) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample. 9. The method of claim 8 wherein said membrane is of the anisotropic type, said membrane being backed by a layer of absorbent capable of sorbing urine. 10. The method of claim 9 wherein the concentration of said protein in the urine is from 0.01 to 1.0%. 11. A test method suitable for detection of pituitary gonadotropins in urine at a concentration as low as about 15 m.I.U./ml of urine, which comprises: (a) clarifying a sample of the urine to be tested through a filter, said filter having been pretreated with an 0.1 to 5.0% aqueous solution of a protein selected from the group consisting of bovine serum albumin, rabbit serum albumin, human serum albumin, gamma globulin, myoglobin, fibrinogen, human hemoglobin, and keyhold limpet hemocyanin so that adsorption of the gonadotropin from the sample onto the membrane is substantially reduced; (b) subjecting about 5 to 50 ml of the clarified urine sample to absorbent induced ultrafiltration through an ultrafiltration membrane having a molecular weight cut-off from about 5,000 to about 50,000, whereby the gonadotropin is retained in the sample; (c) continuing the ultrafiltration until the retentate sample is one-tenth to one-five hundredth its original volume; (d) diluting the retentate sample with sufficient water to provide a retentate sample of about 0.5 ml; and (e) contacting the retentate sample with the appropriate amount of an immunological reagent for detecting the presence of the gonadotropin in the retentate sample. 12. The method of claim 11 in which said membrane is of the anisotropic type having a molecular weight cut-off from about 10,000 to about 35,000 and wherein the concentration of said solution of protein is from 0.1 to 1.0%.

Details for Patent 4,123,510

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		1995-10-31
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		1995-10-31
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		1995-10-31
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		1995-10-31
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		1995-10-31
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		1995-10-31
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		1995-10-31